⌕
MBX Biosciences · MBX · Nasdaq
Tenet 53 · Mixed
Compare
$53.10−0.04%At closeTenet 53 · Mixed
$53.10−0.02 (−0.04%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

MBX Biosciences (MBX) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

1 figure withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Sep 30, 2026: more funds added or entered than trimmed or exited, mild accumulation (14 new · 29 increased · 9 reduced · 2 closed · 5 unchanged or with no prior quarter on file). Flows at this scale move slowly; treat as context. These positions are 49 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 59 filers, Sep 30, 2026
# 13F FUNDS
59
13F VALUE
$187.8M
3.2M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Nov 10, 2026Hoerter Steven L.Chairman, President and CEODisposed · Open-market sale4,893$54.82↗
Nov 4, 2026Azoulay SalomonChief Medical OfficerDisposed · Open-market sale373$53.96↗
Oct 20, 2026Radovich PeterdirectorAcquired · Grant / award18,200Stock option (right to buy)—↗
Aug 4, 2026Azoulay SalomonChief Medical OfficerDisposed · Open-market sale370$65.77↗
Aug 3, 2026Smither John WChief Financial OfficerAcquired · Grant / award28,000—↗
Aug 3, 2026Smither John WChief Financial OfficerAcquired · Grant / award130,000Stock option (right to buy)—↗
Aug 3, 2026Hoerter Steven L.President and CEOAcquired · Grant / award71,000—↗
Aug 3, 2026Hoerter Steven L.President and CEOAcquired · Grant / award331,000Stock option (right to buy)—↗
Jun 4, 2026Mathers Edward TdirectorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Pescovitz Ora H.directorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Heron Patrick JdirectorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Stelzer LauriedirectorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Hoerter Steven L.directorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Ryder StevendirectorAcquired · Grant / award12,500Stock option (right to buy)—↗
Jun 4, 2026Aynechi TibadirectorAcquired · Grant / award12,500Stock option (right to buy)—↗
May 8, 2026Azoulay SalomonChief Medical OfficerAcquired · Option exercise55,000$10.46↗
May 8, 2026Azoulay SalomonChief Medical OfficerDisposed · Open-market sale55,000$38.38↗
May 8, 2026Azoulay SalomonChief Medical OfficerAcquired · Option exercise15,003$16.00↗
May 8, 2026Azoulay SalomonChief Medical OfficerDisposed · Open-market sale15,003$38.30↗
May 8, 2026Azoulay SalomonChief Medical OfficerAcquired · Option exercise55,000Stock option (right to buy)—↗

* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold MBX Biosciences?

MBX Biosciences was held by 59 13F filers as of Sep 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.